Jia-Xin Zhang,Jian-Hao Xu,Bing Yuan,Xiao-Dong Wang,Xu-hu Mao,Jing-Lin Wang,Xiang-Li-Lan Zhang,Yuan Yuan
Detection of Burkholderia pseudomallei with CRISPR-Cas12a based on specific sequence tags
Burkholderia pseudomallei,specific sequence tags,CRISPR-Cas12a,visual detection,species discrimination
Melioidosis is a bacterial infection caused by Burkholderia pseudomallei (B. pseudomallei), posing a significant threat to public health. Rapid and accurate detection of B. pseudomallei is crucial for preventing and controlling melioidosis. However, identifying B. pseudomallei is challenging due to its high similarity to other species in the same genus. To address this issue, this study proposed a dual-target method that can specifically identify B. pseudomallei in less than 40 min. We analyzed 1722 B. pseudomallei genomes to construct large-scale pan-genomes and selected specific sequence tags in their core genomes that effectively distinguish B. pseudomallei from its closely related species. Specifically, we selected two specific tags, LC1 and LC2, which we combined with the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-CRISPR associated proteins (Cas12a) system and recombinase polymerase amplification (RPA) pre-amplification. Our analysis showed that the dual-target RPA-CRISPR/Cas12a assay has a sensitivity of approximately 0.2 copies/reaction and 10 fg genomic DNA for LC1, and 2 copies/reaction and 20 fg genomic DNA for LC2. Additionally, our method can accurately and rapidly detect B. pseudomallei in human blood and moist soil samples using the specific sequence tags mentioned above. In conclusion, the dual-target RPA-CRISPR/Cas12a method is a valuable tool for the rapid and accurate identification of B. pseudomallei in clinical and environmental samples, aiding in the prevention and control of melioidosis.
Detection of Burkholderia pseudomallei with CRISPR-Cas12a based on specific sequence tags

Melioidosis is a bacterial infection caused by Burkholderia pseudomallei (B. pseudomallei), posing a significant threat to public health. Rapid and accurate detection of B. pseudomallei is crucial for preventing and controlling melioidosis. However, identifying B. pseudomallei is challenging due to its high similarity to other species in the same genus. To address this issue, this study proposed a dual-target method that can specifically identify B. pseudomallei in less than 40 min. We analyzed 1722 B. pseudomallei genomes to construct large-scale pan-genomes and selected specific sequence tags in their core genomes that effectively distinguish B. pseudomallei from its closely related species. Specifically, we selected two specific tags, LC1 and LC2, which we combined with the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-CRISPR associated proteins (Cas12a) system and recombinase polymerase amplification (RPA) pre-amplification. Our analysis showed that the dual-target RPA-CRISPR/Cas12a assay has a sensitivity of approximately 0.2 copies/reaction and 10 fg genomic DNA for LC1, and 2 copies/reaction and 20 fg genomic DNA for LC2. Additionally, our method can accurately and rapidly detect B. pseudomallei in human blood and moist soil samples using the specific sequence tags mentioned above. In conclusion, the dual-target RPA-CRISPR/Cas12a method is a valuable tool for the rapid and accurate identification of B. pseudomallei in clinical and environmental samples, aiding in the prevention and control of melioidosis.

Melioidosis is a tropical disease caused by the aerobic, Gram-negative motile bacillus which is classified as a category B biological agent by the Centers for Disease Control and Prevention (CDC) of America (1, 2). It is a highly pathogenic endemic zoonotic disease in many tropical countries, particularly in Southeast Asia and Northern Australia. In China, the southern regions of Hainan, Guangdong, Guangxi, and Fujian are the endemic areas for the disease. Hainan carries the most significant burden compared to other provinces, and residing in or traveling to this tropical island is an important risk factor for infection (3). Hainan also experienced a geographical melioidosis outbreak in Hainan following the 2021 typhoon (4). Epidemiological studies have indicated that melioidosis often affects individuals with one or more pre-existing conditions associated with an altered immune response, such as diabetes, compromised liver or decreased renal function appears to have an increased risk of infection (5). The most severe clinical symptom is sepsis, a life-threatening, dysregulated, systemic inflammatory and immune response that can cause organ dysfunction with a case fatality rate of up to 40%. The number of cases worldwide is estimated to be 165,000 per year, of which 89,000 are fatal (6). The B. pseudomallei strain K96243 has two chromosomes with significant functional partitioning of genes. The large chromosome has 4.07 Mbp and carries many core functions related to central metabolism and cell growth. The small chromosome, with 3.17 Mbp, encodes accessory functions associated with adaptation and survival in different niches. The genome has 7,232 protein coding sequences (CDS), 60 transfer RNA (tRNA) genes, and 12 ribosomal RNA (rRNA) genes. Approximately 6% of the genome consists of putative genomic islands that are likely obtained by horizontal gene transfer (7). There are over 40 species of Burkholderia in the genus, among which B. pseudomallei and Burkholderia mallei (B. mallei), are the most pathogenic. However, they are very similar in genetic and immunological features. Previously, randomly amplified polymorphic DNA (RAPD) (8),16S rRNA gene sequencing (9), multilocus sequence typing (MLST) (10), polymerase chain reaction-restriction fragment length polymorphism (PCR–RFLP) (11), probe-based real-time PCR and loop-mediated isothermal amplification targeting Burkholderia type III secretion system genes (12, 13), multiplex PCR assays (14–16), single-nucleotide polymorphism (SNP) typing (17), DNA microarrays (18) and proteome profiling (19) have been developed to detect and differentiate B. pseudomallei. Unfortunately, the specificity and coverage of the above primers and probes for B. pseudomallei were found to be insufficient after NCBI BLAST website verification. To address these shortcomings, this study aimed to identify unique tags based on genome differences between different species and genera of pathogens, as well as their intraspecific polymorphisms. Recombinase polymerase amplification (RPA) is a thermostatic amplification technology that can expand target DNA to detectable levels in 10 min in an isothermal reaction condition (20). Clustered regularly interspaced short palindromic repeats (CRISPR)—CRISPR associated proteins 12a (Cas12a), a powerful diagnostic tool, has been widely used for the detection of pathogenic bacteria in recent years (21, 22). When the CRISPR-Cas12a system is used to establish a sensing platform for the detection of pathogenic bacteria, Cas12a-crRNA can recognize target DNA and activate the trans-cleavage of Cas12a which will cleave the non-target single-stranded DNA (electrochemistry, fluorescence probe, etc.) (23, 24). Therefore, we can use this feature to develop detection methods in vitro. In this study, we constructed the pan-genome and evaluated gene presence/absence from the genomic sequences of 1722 B. pseudomallei strains and 92 B. mallei strains using Roary software. Subsequently, 44 specific sequence tags for quick identification of B. pseudomallei were found from the core genome sequences (Figure 1A). The specific tags, containing protospacer adjacent motif (PAM) sequences, of B. pseudomallei were selected. Finally, two of the newly developed B. pseudomallei-specific tags, Cas12a as a biosensor coupled with RPA pre-amplification and fluorescent signal output, were used to construct the dual-target RPA-CRISPR/Cas12a assay for rapid, sensitive, and specific detection of B. pseudomallei (Figure 1B).

A total of 1,722 B. pseudomallei genomes (13 newly sequenced and 1709 public) and 92 B. mallei genomes (9 newly sequenced and 83 public) were used in this work. All newly sequenced strains were derived from Beijing Institute of Microbiology and Epidemiology. The genomes of the newly sequenced strains had been uploaded to NCBI (The Bioproject number is PRJNA930628). The publicly available genomes were downloaded from NCBI (B. pseudomallei; B. mallei). The genomic DNA of Brucella melitensis, Brucella abortus, Brucella suis, Brucella canis, Francisella tularensis, Bacillus anthracis, Yersinia pestis, Burkholderia cepacian, Vibrio cholerae, Staphylococcus aureus, Vibrio vulnificus, Vibrio parahaemolyticus, and Salmonella typhi provided by Beijing Institute of Microbiology and Epidemiology were used for the specificity tests.

Burkholderia pseudomallei, B. mallei, B. melitensis, B. abortus, B. suis, B. canis, F. tularensis, B. anthracis, and Y. pestis were cultured in biosafety level 3 (BSL-3) and subsequently heat inactivated. For safety, the inactivated bacteria were recoated, and no bacterial growth was found. Then, the inactivated bacteria were taken out of BSL-3. Vibrio cholerae, Staphylococcus aureus, Vibrio vulnificus, Vibrio parahaemolyticus, and Salmonella typhi were cultured in biosafety level 2 (BSL-2). Subsequently, the QIAampTM DNA Mini Kit (Qiagen, Germany) was used to extract genomic DNA from all the bacteria. Extracted DNA was stored at 4°C for a short time or at −40°C for longer periods.

Whole genome de novo sequencing was performed using Illumina MiSeq (Illumina, San Diego, CA, United States) to generate multiplexed paired-end libraries with an average insert size of 300 bp. Next, the raw short-read sequences of each strain were filtered for low-quality data using the FASTQ Quality Filter module in the FASTX-Toolkit software (25). Then, the filtered reads were assembled using the SPAdes 3.0-based software Shovill version 1.0.4 (26) with default settings. The average genome size and GC content of all sequenced strains were 7.11 Mbp and 68.22%, respectively. The detailed description of assembly results was provided in Supplementary Table S1.

The SNPs were identified through pairwise comparisons of 11 previously published Burkholderia genomes (Burkholderia cenocepacia J2315, Burkholderia cenocepacia HI2424, Burkholderia ambifaria AMMD, Burkholderia dolosa AUO158, Burkholderia ubonensis MSMB22, Burkholderia ubonensis Bu, Burkholderia pseudomallei K96243-1, Burkholderia pseudomallei K96243-2, Burkholderia mallei ATCC 23344, Burkholderia mallei SAVP1, and Burkholderia thailandensis E264) using MUMmer 3.0 (27). Then, SNPs in repeated regions with low-quality scores (<20) or supported by few reads (<10 paired-end reads) were eliminated. The maximum likelihood tree (MLTree) was built using RaxML (28) based on the concatenated SNPs.

We annotated 1722 genomes of B. pseudomallei and 92 genomes of B. mallei using Prokka (29). The GFF3 files of B. pseudomallei and B. mallei generated by Prokka were then used in Roary (30) (parameter settings: -cd 100 -i 90 -e -mafft -p 4 -r -t 11) to identify the pan-genome and gene presence/absence. The unique core genome of B. pseudomallei, core base pairs/genes found in all strains of B. pseudomallei but not present in the pan-genome of B. mallei, were screened for subsequent analysis using an in-house Perl script (Supplementary Table S2).

To verify the specificity of the sequence tags, the core genome sequences of B. pseudomallei were further aligned using a local version of the NCBI BLASTN software and NCBI BLAST website. The identified sequence tags were only aligned to the genome sequences of B. pseudomallei, with 100% coverage and identity with all 1722 B. pseudomallei genome sequences. We then selected one specific sequence tag, containing PAM sequences for Cas 12a, on each of the two chromosomes of B. pseudomallei. These two specific sequence tags were named LC1 and LC2, and corresponding PCR primers were designed and synthesized.

The pre-amplification efficiency of RPA is an important for the detection sensitivity. RPA primers (LC1-F1 ~ F4/LC1-R1 ~ R4 and LC2-F1 ~ F4/LC2-R1 ~ R4) were designed by Primer Premier 6.0 according to the assay design manual of the TwistAmp™ DNA amplification kits. RPA probes LC1-P and LC2-P were designed from the amplified sequences of LC1-F/R and LC2-F/R, respectively. These candidate primers were screened with the same concentrations of positive reference plasmid (pEASY-T1-LC1 and pEASY-T1-LC2) as template DNA using the real-time RPA method, performed according to the TwistAmp™ exo Kit (Cambridge, United Kingdom) Quick Guide at 39°C for 10 min in a Genie-II (OptiGene, United Kingdom). The crRNA spacer sequences were designed downstream of the PAM sequence containing 5′-TTTN-3′ on the RPA amplified sequence. The direct repeat sequence was added upstream of the crRNA spacer sequences (31). Particularly, LC1-crRNA-1 and LC1-crRNA-2 were designed by the amplified sequence of LC1-F/R, whereas LC2-crRNA-1 and LC2-crRNA-2 were designed by the amplified sequence of LC2-F/R. Subsequently, the fluorescent single-stranded DNA reporter (Flu-ssDNA) modified with fluorophore 6-FAM and quencher BHQ1 was trans-cleaved by Cas12a, which allowed the identification of the presence or absence of the target genes LC1 and LC2. The RPA primers, RPA probes, crRNA, and Flu-ssDNA were synthesized by Shanghai Sangon Biotech Co., Ltd. (China). Details of the oligonucleotides were listed in Table 1.

Template DNAs were amplified for 30 min in a Genie-II at 39°C according to the TwistAmp™ Basic Kit (Cambridge, United Kingdom) Quick Guide to obtain RPA amplification products. The following CRISPR reaction system was composed of 40 μL reaction solution: 0.3 μL Cas12a (75 nM), 2 μL Flu-ssDNA (500 nM), 0.5 μL RNase inhibitor, 3 μL NEBuffer3.1, 10 μL crRNA (500 nM) and 4.2 μL double-distilled water (ddH2O). LbCas12a protein, NEBuffer 3.1, and RNA inhibitor were provided by NEW ENGLAND BioLabs, Inc. (United States). DNase/RNase-free distilled, deionized water (ddH2O) was provided by Tiangen Biochemical Co., Ltd. Positive reference plasmids for B. pseudomallei detection (pEASY-T1-LC1 and pEASY-T1-LC2) were constructed by our lab. Finally, we took 20 μL of the RPA-amplified product as a template, and then ran the CRISPR/Cas12a reaction system for 10 min at 37°C in the Genie-II.

After identifying the best RPA primers and crRNAs, the sensitivity of the dual-target RPA-CRISPR/Cas12a assay was evaluated. Sensitivity was tested by gradually diluting 2 μL (0.1 ~ 100 copies/μL) of two positive plasmids (0.2 ~ 200 copies/reaction), and 2 μL (1 ~ 100 fg/μL) of B. pseudomallei genomic DNA (2 ~ 200 fg) were used as template DNA to test the sensitivity. The specificity of the dual-target RPA-CRISPR/Cas12a assay for B. pseudomallei was investigated with low input B. pseudomallei genomic DNA (100 fg) as well as high input B. mallei genomic DNA (100 pg) and 12 non-B. pseudomallei bacterial genomic DNA (100 pg). DDH2O was used as a no-template control (NTC). Twelve non-B. pseudomallei bacterial genomic DNA were prepared by mixing the genomic DNA of 12 other pathogenic bacteria, including B. melitensis, B. abortus, B. suis, B. canis, F. tularensis, B. anthracis, Y. pestis, V. cholerae, S. aureus, V. vulnificus, V. parahaemolyticus, and S. typhi.

As B. pseudomallei bacteria are highly pathogenic and must be handled under BSL-3 conditions (Manual of Clinical Microbiology, 8th ed., American Society for Microbiology, Washington, DC), we only use the genomic DNA to prepare test samples. To verify the feasibility of the dual-target RPA-CRISPR/Cas12a assay for B. pseudomallei, a total of 12 blood samples and 12 moist soil samples were collected. In a double-blinded test, different concentrations of B. pseudomallei genomic DNA (between 200 and 10 fg/μL), B. mallei genomic DNA (1 × 105 fg/μL), and B. cepacia genomic DNA (1 × 105 fg/μL), as well as a blank control (BC) sample with ddH2O, were added. DNA was extracted with the QIAamp DNA Mini kit, and 2 μL nucleic acid extract was used for real-time PCR (RT-PCR) and the dual-target RPA-CRISPR/Cas12a assay for B. pseudomallei. The RT-PCR assay for B. pseudomallei was performed according to a previously published method (32) in the qTOWER3G instrument (Analytikjena, Germany) with the following program: pre-denaturation at 95°C for 2 min, followed by 45 cycles of denaturation at 95°C for 5 s and annealing and extension at 56°C for 10 s, 72°C for 10 s, and 40°C for 20 s. The results of the RT-PCR and the dual-target RPA-CRISPR/Cas12a assays for B. pseudomallei were then analyzed and compared.

The 10 min fluorescence signals of each group were collected from Genie-II. The experimental data of each group was normalized to create an intuitive heat map. At the same template DNA concentration, a profound color and a normalized value closer to 1.00 are indicative of a greater fluorescence signal. The fold change value (FCV) in the fluorescence of each group was calculated as the average fluorescence value of each testing group divided by the average fluorescence signal of the no-template control (NTC) group.

According to the results of NCBI BLAST website verification, we found that the published primers and probes for B. pseudomallei were insufficiently specific and covered (Supplementary Table S3).

This study analyzed the whole genomes of 1722 of B. pseudomallei strains and 92 B. mallei strains isolated between 1996 and 2019, from six continents and more than 40 countries. The construction of phylogenetic trees shows genetic distances and relationships between individuals within a population and is therefore useful for studying population structure and species evolution. Phylogenetic analysis demonstrated that B. pseudomallei and B. mallei were the most closely related but still clearly distinguishable (Supplementary Figure S1). The numbers of gene families for B. pseudomallei and B. mallei were calculated using MUMmer and Roary. From the total of 28,206 genes in the B. pseudomallei pan-genome, we identified 945 core genes (99% ≤ strains≤100%), 3,868 soft core genes (95% ≤ strains<99%), 868 shell genes (15% ≤ strains<95%) and 22,525 cloud genes (0% ≤ strains<15%). Of the 5,973 genes of the B. mallei pan-genome, we identified 2,591 core genes, 1,047 soft core genes, 1,197 shell genes, and 1,138 cloud genes (Figure 2A). As the number of strains increased, the number of core genes gradually decreased, and the number of pan genes increased, suggesting that the genetic material of B. pseudomallei and B. mallei is still “open” with high genetic diversity (Figure 2B). We also identified unique core genome sequences of B. pseudomallei using an in-house Perl script (Figure 1A).

Sequences fragments on the B. pseudomallei core genome with a length of >5,000 bp were chosen to boost detection specificity. In total, 44 B. pseudomallei-specific sequence tags were screened using a local version of the NCBI BLASTn and online NCBI BLAST that contain all the public genomes up to date (Supplementary Table S4). The results showed that all the 44 B. pseudomallei-specific sequence tags were identical to the sequences of the B. pseudomallei species with query cover and sequence identity being both 100%. Also, The B. pseudomallei-specific sequence tags were inconsistent with non-B. pseudomallei species and strains and could therefore be used to identify B. pseudomallei. We selected two B. pseudomallei-specific sequence tags to detect B. pseudomallei and named them LC1 and LC2 sites (Figure 3).

Initially, RPA fluorescent probes LC1-P and LC2-P were used to cross-screen the designed RPA primers LC1-F1 ~ F4/LC1-R1 ~ R4 and LC2-F1 ~ F4/LC2-R1 ~ R4. The screening results for the LC1-RPA primers were shown in Figure 4A. Primers LC1-F2/R3 (0.76) and LC1-F2/R4 (1.00) had preferably normalized values. The screening results for the LC2-RPA primers were shown in Figure 4B. Primers LC2-F4/R3 (0.66) and LC2-F4/R4 (1.00) had preferably normalized values. After preliminary screening of RPA primers, crRNA was designed to construct the CRISPR/Cas12a system, and RPA was used for pre-amplification to establish the RPA-CRISPR/Cas12a method. The candidate primers LC1-F2/R3 and LC1-F2/R4 were combined with LC1-crRNA-1 and LC1-crRNA-2, respectively. The candidate primers LC2-F4/R3 and LC2-F4/R4 were combined with LC2-crRNA-1 and LC2-crRNA-2, respectively. Two positive reference plasmids (10 copies/μL, 2 μL) were used as template DNA and the primer, combinations were screened with the RPA-CRISPR reaction. For LC1, the primer LC1-F2/R3 combined with LC1-crRNA-1 had the greatest normalized value (Figure 4C). For LC2, the primer LC2-F4/R4 combined with LC2-crRNA-2 had the greatest normalized value and was therefore used to establish the LC2 RPA-CRISPR/Cas12a assay for B. pseudomallei (Figure 4D).

The sensitivity of the dual-target RPA-CRISPR/Cas12a assay was evaluated. Obviously, two assays completed the detection of target DNA within 40 min, requiring 30 min for RPA and 10 min for CRISPR (Figures 5B,D,F,H). The LC1 RPA-CRISPR/Cas12a assay showed a low detection limit for Burkholderia pseudomallei at 0.2 copies/reaction and 10 fg genomic DNA (Figures 5A–D). LC2 RPA-CRISPR/Cas12a assay showed a low detection limit for B. pseudomallei down to 2 copies/reaction and 20 fg genomic DNA (Figures 5E–H). The specificity of the dual-target RPA-CRISPR/Cas12a assay for B. pseudomallei was investigated with low input B. pseudomallei genomic DNA (100 fg) as well as high input B. mallei genomic DNA (100 pg) and 12 non-B. pseudomallei bacterial genomic DNA (100 pg). DDH2O was used as a no-template control (NTC). As shown in Figures 6A,B, the dual-target RPA-CRISPR/Cas12a assay was only positive for B. pseudomallei. In addition, for testing 8 strains of B. pseudomallei (101, 103, 118,120, 121, 122, 127, 171) and 8 strains of B. mallei (012, 017, 020, 021, 023, 024, 028, 029) (Figures 6C,D), the dual-target RPA-CRISPR/Cas12a assay distinguishes specific detection of B. pseudomallei.

After completion of the sensitivity and specificity evaluations, we analyzed the clinical adaptation feasibility of the dual-target assay using clinical samples, derived from human blood, and environmental samples, derived from naturally moist soil. Concomitantly, RT-PCR was used as an auxiliary reference experiment. We analyzed the feasibility of the RT-PCR assay and used it to quantify the genomic DNA spiked into the simulated samples. A dilution gradient of B. pseudomallei genomic DNA (1 ng, 100, 10, 1 pg., and 100 fg) in ddH2O for constructing the standard curve of the RT-PCR assay, while the ddH2O was set to NTC synchronously (Supplementary Figure S2), R2 > 0.99, Y = 3.182*X + 23.56. The results of the dual-target RPA-CRISPR/Cas12a and RT-PCR assays for clinical and 12 environmental samples were shown in Figure 7. The LC1/LC2 RPA-CRISPR/Cas12a assay detected all positive blood samples. However, the RT-PCR assay, only detected No. 2, 4, 8, and 9 positive blood samples and could not effectively detect lower concentrations of the positive samples (Figure 7A). The test results showed that the LC1/LC2 RPA-CRISPR/Cas12a assay has significantly lower sensitivity for positive moist soil samples (Figure 7B, No. 5, 9, and 10), than for blood samples in detecting positive moist soil samples (Figure 7A, No. 1, 4, and 10). The RT-PCR assay failed to detect all positive environmental samples. This might be attributed to the low extraction efficiency of small quantities of target DNA spiked in complex samples. Furthermore, the RT-PCR assay and the dual-target RPA-CRISPR/Cas12a assay did not have cross-reactions with B. mallei and B. cepacia (Figures 7C,D) in two simulated samples. Therefore, whether in blood samples or more complex soil samples, the dual-target RPA-CRISPR/Cas12a assay showed superior detection results to the RT-PCR assay. More importantly, the dual-target RPA-CRISPR/Cas12a assay had the advantage of a short detection time, which facilitated on-site testing of melioidosis.

B. pseudomallei is a gram-negative bacterium found in soil and water in tropical and subtropical regions of the world (33, 34). B. pseudomallei causes melioidosis, as a potential bioterror agent, that poses a threat to biosecurity. In addition to being a human pathogen, B. pseudomallei can infect and cause disease in cattle, pigs, goats, horses, dolphins, koalas, kangaroos, deer, cats, dogs, and gorillas. A report had called for action: time to recognize melioidosis as a neglected tropical disease (35). A more rapid and sensitive detection method is required for monitoring B. pseudomallei infection and for the prevention and treatment of melioidosis. Various methods (8) have previously been attempted to identify B. pseudomallei. However, it is difficult to distinguish B. pseudomallei from Burkholderia and other closely related species due to their high phenotypic and genetic similarity. To remedy these deficiencies, here we had obtained 44 specific sequence tags of B. pseudomallei by bioinformatic analysis. Two of these tags on chromosome 1 and chromosome 2 of B. pseudomallei were used to develop a dual-target detection method. Notably, the selection of dual targets on core genomes (genes present in all strains) of two chromosomes were more conservative, stable, and less prone to horizontal gene transfer because B. pseudomallei is a high-frequency recombinant bacterium (36). The other 42 specific sequence tags will also provide important clues for the development of molecular diagnostic techniques for melioidosis in the future. The RPA primers and crRNAs we designed were based on the selected sequences of B. pseudomallei, respectively. RPA specifically amplified the pathogen target, and then the crRNA/Cas12a/amplification product formed a ternary complex. Studies have shown that Cas12a has a single-base recognition ability, which gives the technology high specificity (31). Depending on the advantages of specificity, rapidity, ultrasensitivity, and covering two chromosomes, the dual-target RPA-CRISPR/Cas12a assay developed in this study will play an important role in the accurate and rapid diagnosis of B. pseudomallei in clinical and field, and will also fill the gap in CRISPR-based vitro diagnosis of melioidosis, which serves as a valuable reference for subsequent research.

We identified 44 specific sequence tags from the core genome sequences of chromosomes 1 and 2 of B. pseudomallei by bioinformatics methods, and two of them were used to develop a dual-target RPA-CRISPR/Cas12a detection method for highly specific identification of B. pseudomallei. The specific, rapid, and ultrasensitive detection, as well as the inclusion of both chromosomes, will allow the dual-target assay to play an important role in the accurate and rapid diagnosis of B. pseudomallei in clinical and field settings, as well as improving CRISPR-based in vitro diagnosis of melioidosis. Our study therefore has great potential for B. pseudomallei detection and the prevention and treatment of melioidosis. In summary, our study enriches the potential of in vitro diagnosis of pathogenic bacteria based on CRISPR. In addition, this study can be extended to other pathogenic bacteria detection applications, especially when phenotypic and genetic similarity makes it difficult to distinguish between the same genus and the same species of pathogenic bacteria. However, more work needs to be done to apply the technology to practical applications, such as nucleic acid-free extraction and the development of integrated microfluidic detection.

The data has been successfully deposited on NCBI and the Bioproject number is PRJNA930628. Additionally, the raw data for figures is provided in the Supplementary information.

YY and X-L-LZ designed the study. J-XZ and YY wrote the manuscript. J-XZ, J-HX, and BY constructed CRISPR-Cas12a detecting platform. X-L-LZ and J-XZ performed bioinformation analysis. BY and X-DW performed DNA extraction and RT-PCR of samples. YY, J-XZ, and J-HX analyzed the data. X-hM provided some B. pseudomallei genomic DNA. YY and J-LW contributed project administration. All authors contributed to the article and approved the submitted version.

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpubh.2023.1153352/full#supplementary-material Click here for additional data file. Click here for additional data file. Click here for additional data file.